Carcinotech

Carcinotech is a Scottish-based medtech company that has developed a groundbreaking 3D printing technology called Carcino3D. This technology enables the manufacture of 3D-printed micro-tumors using patient-derived biopsies, primary cells, immune cells, and cancer stem cells. These 3D-printed micro-tumors serve as simulations of the tumor microenvironment and can be used for rapid, ethical, and accurate drug screening, preclinical testing, and personalized medicine testing.

Carcinotech's offerings aim to accelerate the development of new life-saving cancer treatments and contribute to personalized medicine. The company's 3D-printed tumors are more complex than organoids, incorporating up to 16 or 17 different cell types and allowing for comprehensive immune profiling. This complexity, coupled with the ability to produce hundreds of consistent 3D-printed samples from a single patient sample, sets Carcinotech's technology apart from traditional organoid models.

Carcinotech's 3D-printed tumors are available for various cancers, including lung, brain, breast, colorectal, and ovarian cancers, with plans to develop models for pediatric cancers and vascularized tumors. The company's technology has the potential to significantly reduce the costs and timelines associated with preclinical drug testing, enabling pharmaceutical companies to conserve capital and accelerate the drug development process.

In October 2023, Carcinotech announced a partnership with CELLINK, a leader in bioprinting solutions, to develop and commercialize protocols for biofabricated 3D bioprinted tumor models based on cancer cell lines. This collaboration aims to provide improved speed and accuracy in drug development processes.